A groundbreaking study analysing data from nearly 600,000 cancer patients in England has shed light on the increased risk of second cancers among breast
cancer survivors.
The research conducted by University of Cambridge in association with the Lancet Regional Health-Europe studied data from over 580,000 female and over 3,500 male
breast cancer survivors diagnosed between 1995 and 2019 using the National Cancer Registration Dataset.
The findings suggest that survivors of breast cancer, the most prevalent cancer in the UK, face a substantially higher risk of developing second primary cancers.
According to the research, female survivors exhibited a twofold increase in the risk of contralateral breast cancer compared to the general population.
The data highlighted an 87 per cent greater risk of endometrial cancer, a 58 per cent greater risk of myeloid leukemia, and a 25 per cent greater risk of ovarian
cancer in female survivors.
New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer.
The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units,
a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent).
This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies.
Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier.
The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around
13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.
The NHS is going to roll out a revolutionary 30-minute treatment for advanced womb cancer for women across England.
The drug, called Dostarlimab, would benefit around 100 women with advanced and often incurable endometrial cancer every year after the NHS agreed early access to the treatment through the Cancer Drugs Fund.
It works by attaching to a specific protein on the surface of the cancer cells, helping the immune system to detect and attack it.
The treatment takes just 30 minutes to administer through the blood stream every three weeks over a 12-week period.
The move is in line with the NHS Long Term Plan which aims to provide the latest cutting-edge treatments and therapies for patients.
Hi friends ,sorry for a delayed posting.Today i'll briefly review the RISK FACTORS OF BREAST CANCER.Breast cancer is a very common cancer.Breast cancer is perhaps the most common cancer in women of the developed countries.